Firefly Discovers PTSD Biomarker via FDA-Cleared Evoke System Using NVIDIA L40S GPUs
AIFF•Firefly identified a novel electrophysiological biomarker for PTSD using its FDA-cleared Evoke System through its U.S. Department of War partnership targeting military personnel. The AI-driven study leveraged NVIDIA L40S GPUs to analyze EEG data, making Firefly the only company with both an active government partnership and a PTSD biomarker.
1. Discovery of Novel PTSD Biomarker
Firefly’s Evoke System, cleared via FDA 510(k), identified a consistent electrophysiological signal distinguishing PTSD patients from healthy controls. This represents Firefly’s first identified neural marker for PTSD and deepens its scientific foundation for objective brain health assessment.
2. Technology and AI Infrastructure
The biomarker finding was powered by Firefly’s deep learning architecture running on NVIDIA L40S GPU-accelerated infrastructure. High-throughput analysis of multi-channel EEG data enabled the detection of resting-state hyperarousal patterns and abnormal cognitive responses at unprecedented scale.
3. U.S. Department of War Partnership
This discovery follows Firefly’s active public-private partnership with the U.S. Department of War to assess and treat PTSD and TBI in active-duty personnel and veterans. Firefly is now the only company combining an identified PTSD biomarker with an established government brain-health deployment.
4. Commercial Pathways and Competitive Edge
The PTSD-specific biomarker could expand Firefly’s engagement in three channels: government brain health, pharmaceutical clinical trials as an objective endpoint, and clinical psychiatry for personalized treatment. Its proprietary database and GPU-driven AI platform create a competitive advantage across defense, pharma and mental health markets.
